{
  "date": "2026-02-10",
  "generated_at": "2026-01-18T20:27:47.555663+08:00",
  "source_count": 5,
  "item_count": 5,
  "takeaways": [
    "FiercePharma: Pfizer's RSV shot wins EMA nod",
    "Endpoints News: Moderna posts Phase III melanoma win with Keytruda combo",
    "PharmaTimes: AstraZeneca, EQRx terminate $1B licensing deal"
  ],
  "categories": [
    {
      "id": "regulatory",
      "name": "Regulatory Decisions / 监管审批",
      "items": [
        {
          "title": "FDA approves Eli Lilly's oral obesity drug Orizea",
          "insight": "CDER granted priority approval to Orizea for chronic weight management, making Lilly the first oral entrant against GLP-1 incumbents.",
          "source": "FDA CDER",
          "url": "https://www.fda.gov/news-events/press-announcements/orizea-approval",
          "published_local": "2026-02-10T11:15:00+08:00"
        },
        {
          "title": "Moderna posts Phase III melanoma win with Keytruda combo",
          "insight": "Moderna and Merck reported a 35% reduction in recurrence for their mRNA vaccine + Keytruda regimen, and plan FDA submission later this year.",
          "source": "Endpoints News",
          "url": "https://endpts.com/moderna-keytruda-phase3",
          "published_local": "2026-02-10T09:00:00+08:00"
        },
        {
          "title": "Pfizer's RSV shot wins EMA nod",
          "insight": "The European Medicines Agency recommended approving Pfizer's RSV vaccine for adults 60+, paving the way for a commercial launch across the bloc.",
          "source": "FiercePharma",
          "url": "https://www.fiercepharma.com/pharma/pfizer-rsv-ema",
          "published_local": "2026-02-10T07:30:00+08:00"
        }
      ]
    },
    {
      "id": "launch",
      "name": "Drug Launches / 上市与商业化",
      "items": [
        {
          "title": "AstraZeneca, EQRx terminate $1B licensing deal",
          "insight": "AstraZeneca and EQRx mutually ended their asset licensing pact as pricing reforms reshape the US market; both parties will explore new collaborations.",
          "source": "PharmaTimes",
          "url": "https://www.pharmatimes.com/news/astrazeneca-eqrx",
          "published_local": "2026-02-10T02:00:00+08:00"
        }
      ]
    },
    {
      "id": "clinical",
      "name": "Clinical Trials / 临床试验",
      "items": [
        {
          "title": "Phase II study shows Takeda's oral Crohn's therapy meets endpoints",
          "insight": "Takeda disclosed top-line Phase II data showing its oral TYK2 inhibitor achieved clinical remission at week 12, setting up a Phase III start in H2.",
          "source": "ClinicalTrials.gov",
          "url": "https://clinicaltrials.gov/study/takeda-tyk2",
          "published_local": "2026-02-10T00:00:00+08:00"
        }
      ]
    }
  ],
  "keywords": [
    {
      "name": "辉瑞 Pfizer",
      "heat": "低",
      "count": 1
    },
    {
      "name": "莫德纳 Moderna",
      "heat": "低",
      "count": 1
    },
    {
      "name": "默沙东 Merck",
      "heat": "低",
      "count": 1
    },
    {
      "name": "阿斯利康 AstraZeneca",
      "heat": "低",
      "count": 1
    },
    {
      "name": "礼来 Eli Lilly",
      "heat": "低",
      "count": 1
    },
    {
      "name": "武田 Takeda",
      "heat": "低",
      "count": 1
    },
    {
      "name": "RSV疫苗",
      "heat": "低",
      "count": 1
    },
    {
      "name": "GLP-1",
      "heat": "低",
      "count": 1
    }
  ],
  "sources": [
    "ClinicalTrials.gov",
    "Endpoints News",
    "FDA CDER",
    "FiercePharma",
    "PharmaTimes"
  ],
  "stats": {
    "Regulatory Decisions / 监管审批": 3,
    "Drug Launches / 上市与商业化": 1,
    "Clinical Trials / 临床试验": 1
  }
}